Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline : Thinfilm and GlaxoSmithKline Bring NFC Technology to Leading Over-the-Counter Brand Flonase

share with twitter share with LinkedIn share with facebook
share via e-mail
10/03/2017 | 08:31am CEST

 Interactive 'Smart' Shelves Featuring NFC SpeedTap Tags Educate Consumers and
  Drive Purchasing Decisions; Program Launched in Retail Stores Across Canada

OSLO, Norway, October 3, 2017 - Thin Film Electronics ASA ("Thinfilm") (OSE:
THIN; OTCQX: TFECY), a global leader in NFC (near field communication) mobile
marketing and smart packaging solutions, today announced that GlaxoSmithKline
("GSK") (LSE/NYSE: GSK), one of the world's leading research-based
pharmaceutical and healthcare companies has commercially deployed Thinfilm's
unique SpeedTap(TM) tags to create interactive 'smart' shelves for enhanced
communication with consumers at time of purchase decision-making.

GSK introduced interactive 'smart' Flonase® shelves in retail stores across
Canada in an effort to educate consumers about the new product and guide them in
their purchasing decision. Thinfilm's unique SpeedTap(TM) tags incorporated into
shelving allows consumers to obtain product information through the tap of an
NFC-enabled smartphone.

In addition to SpeedTap tags, GSK is also using Thinfilm's software platform -
CNECT(TM) - as part of the end-to-end solution that helps dynamically manage the
experience of Flonase® consumers. The cloud-based platform integrates with the
NFC hardware, enabling GSK to manage tags remotely, deliver custom messaging and
content, view real-time consumer tapping activity, and develop valuable consumer
insights through built-in analytics functionality.

"At GSK, we focus on helping people do more, feel better, and live longer. And
we do that, in large part, by delivering highly effective products to the
market," said Sriman Banerjee, Director - R&D Respiratory Packaging for GSK.
"But we also realize that connecting directly with consumers to provide unique
and meaningful experiences is critical in today's market. We believe an
innovative mobile technology like Thinfilm's can play a critical role in
strengthening customer relationships, building brand loyalty, and driving
revenue for the Flonase® brand."

Flonase® Allergy Relief is the first 'prescription to over-the-counter'
intranasal corticosteroid spray from GSK indicated for relief of nasal and eye-
related allergy symptoms as well as management of sinus pain and pressure. It is
an effective medicine that relieves seasonal and year-round allergy symptoms
caused by pollen, mold, dust and pets.

"We are delighted to work with GSK - a global leader, an innovator, and a
company that is changing the face of healthcare," said Davor Sutija, CEO of
Thinfilm. "Bringing Thinfilm's NFC solutions to a valued product like Flonase®
is a milestone in the industry, and we look forward to helping GSK drive the
brand's value by connecting directly with consumers at the time of purchase

About Thin Film Electronics ASA
Thinfilm is a global leader in NFC mobile marketing and smart-packaging
solutions using printed electronics technology. The Company creates printed
tags, labels, and systems that include memory, sensors, displays, and wireless
communication - all at a cost-per-function unmatched by conventional electronic
Thinfilm offers end-to-end mobile marketing solutions that feature hardware,
label/packaging integration services, and comprehensive cloud-based management,
reporting and analytics. Collectively, these components deliver a powerful 1-to-
1 digital marketing platform through which brands of all sizes can connect
directly with consumers, all with the simple tap of a smartphone. The resulting
disintermediation of search engines, online marketplaces, and social platforms
empowers brands to control messaging, enhance consumer dialogue, build loyalty,
increase engagement, and drive sales.
Thinfilm's roadmap integrates technology from a strong and growing ecosystem of
partners to bring intelligence to everyday, disposable items. Its mission is to
effectively extend the traditional boundaries of the Internet of Things to fuel
the Internet of Everything.
Thin Film Electronics ASA is a publicly listed company in Norway with global
headquarters in Oslo, Norway; US headquarters in San Jose, California; and
offices in Linköping, Sweden; San Francisco; London; and Shanghai. For more
information, visit www.thinfilm.no.

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest consumer
healthcare products companies. Its more than 30 well-known brands include
Voltaren®, Emulgel®, Aquafresh®, Sensodyne®, and TUMS®.

About GlaxoSmithKlineGlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For company information
visit: http://www.gsk.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act).

For more information on Thinfilm please contact:
Bill CummingsSVP Corporate CommunicationsThin Film Electronics ASA
+1 408-503-7312
[email protected]

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Thin Film Electronics ASA via GlobeNewswire


© InPublic, source European Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.53% 1549.8 Delayed Quote.17.19%
THIN FILM ELECTRONICS ASA -1.62% 1.82 Delayed Quote.-25.40%
share with twitter share with LinkedIn share with facebook
share via e-mail
07/21GLAXOSMITHKLINE : US FDA approves Krintafel (tafenoquine) for the radical cure o..
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
07/20GLAXOSMITHKLINE : considers splitting up the group
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
07/20ASTRAZENECA : EU drug regulators step up work to prepare for 'no deal' Brexit
07/20GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc in the Area of Biomarkers Des..
07/19GLAXOSMITHKLINE : New Findings from GlaxoSmithKline plc Update Understanding of ..
07/18Novartis hints at 2018 outlook hike despite drug price freeze
07/18GLAXOSMITHKLINE : ViiV Healthcare shares data from landmark 2-drug regimen trial..
07/18Novartis hints at 2018 outlook hike despite drug price freeze
More news
News from SeekingAlpha
07/20GlaxoSmithKline reportedly mulling breakup; ADRs jump nearly 3% 
07/20Key events next week - healthcare 
07/19Liquidia Technologies Readies $50 Million IPO 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars